Retaane “Approvable” For Macular Degeneration; Alcon Plans July Meeting With FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alcon expects to meet with FDA in July to discuss a May 23 "approvable" letter for its wet age-related macular degeneration agent Retaane (anecortave acetate suspension)